The Roskamp Institute, Inc.
Welcome,         Profile    Billing    Logout  
 7 Trials 
6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Burke, Deborah
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Keegan, Andrew
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Abdullah, Laila
No trials found
Cinor, Sandra
No trials found
Alvarez, Yahdinah
No trials found
Davis, Lois
No trials found

Download Options